IONS News and Press, Ionis Pharmaceuticals Inc. From 04/19/24

2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...

2024-04-17 08:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Historic mega cap conc...

2024-04-12 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-12 07:20:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The positive momentum ...

2024-04-10 12:03:39 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain Ionis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transc...

2024-04-09 18:30:03 ET Wolfe Research analyst issues OUTPERFORM recommendation for IONS on April 9, 2024 04:39PM ET. IONS was trading at $42.83 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 -...

2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...

2024-04-08 10:16:48 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) on Sunday announced positive results from a late-stage study of its lead investigational drug, olezarsen.... Read the full article on Seeking Alpha For further details see: Ionis experimental drug meet...

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome PR Newswire – Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful...

Ionis to hold olezarsen Phase 3 data webcast PR Newswire Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif. , March 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it wil...